¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2020-10-31

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2020-10-31
±³À°ÀÏÀÚ : 2020-10-31
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À° (½Ç½Ã°£ È­»ó°­ÀÇ/¿Ü±¹ÀÎ ¿¬ÀÚ ³ìÈ­°­¿¬ ¿µ»ó ¼ÛÃâ)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö      
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì 
¿¬¶ôó : 02-512-0044  
À̸ÞÀÏ : gyncancer@gyncancer.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 9 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í Àü¹®ÀÇ 60,000 Àü°øÀÇ 45,000 ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:30~08:40 Opening Remarks  ±è½Âö(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:40~08:50 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ³í¹® ¹ßÇ¥  ¹è´ö¼ö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 08:50~09:00 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ³í¹® ¹ßÇ¥  ±è¿µÅ¹(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:00~09:20 The best type of PARPi for the best time in the management of ovarian cancer  À̽ÅÈ­(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:20~09:40 The best type of PD1 inhibitor for the best time in the management of cervical cancer  ÀÌ¿ø¹«(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 09:40~10:00 PD1 inhibitor with/without multiple kinase inhibitor for the treatment of endometrial cancer  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:00~10:20 Which phase II/III RCTs in ovarian cancer will be finalized in 5 year?  À¯ÇåÁ¾(Ãæ³²ÀÇ´ë) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:20~10:30 Discussion  () 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:30~10:50 Secondary cytoreductive surgery in recurrent epithelial ovarian cancer ÀÌ  ÀÌ»êÈñ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 10:50~11:10 Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:10~11:30 ADC(Antibody-Drug Conjugate) in management of ovarian cancer  Á¶ÇѺ°(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:30~11:50 Novel discoverise in endometrial cancer: are we making progress?  À̼ºÁ¾(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 11:50~12:10 Screening for lynch syndrome in endometrial cancer patients  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 12:10~12:20 Discussion  () 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 12:20~12:40 Rationale for earlier intervention with PARP inhibitor and importance of personalized medicine in ovarian cancer  ±è±âµ¿(¼­¿ïÀÇ´ë) 
½Ä»ç 10¿ù 31ÀÏ  12:40~13:40 Lunch  () 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 13:40~14:00 Quality control of surgery in advanced epithelial ovarian cancer  Christina Fotopoulou(Imperial College London, UK) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:00~14:05 Discussion  ±èÈñ½Â(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:05~14:25 Current and future considerations for the use of checkpoint inhibitors in gynecologic cancers  David O(The Ohio State University, USA) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:25~14:30 Discussion  ¾î°æÁø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:30~14:45 An introduction to NUWA-National gynecological oncology research and patient management platform  Qinglei Gao(Huazhong University, China) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:45~14:50 Discussion  ±è¼¼ÀÍ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 14:50~15:10 9°¡ ÀڱðæºÎ¾Ï ¿¹¹æ¹é½Å Çã°¡ »çÇ× - Áø·á±Ç°í¾È ¾÷µ¥ÀÌÆ®  ¹Î°æÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:10~15:30 Future treatment strategy based on PARPi frontline ovaian cancer  Antonio González-Martín(Clínica Universidad de Navarra, Spain) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:30~15:50 Patient blood management as a standard of care  ÀÌÁ¤Àç(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 15:50~16:00 Perioperative use of IV iron in gynecologic cancer patients (Áõ·Ê¹ßÇ¥)  ¼­µ¿ÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 16:00~16:30 Clinical impact of febrile neutropenia with ovarian cancer by pegfilgrastim  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(Çмú Program) 16:30~16:40 Discussion  () 
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 13:30~13:40 Opening Remarks  ³ëÁÖÈñ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ °£È£ºÐ°ú¼ÒÀ§¿øÀå) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 13:40~14:00 Recent clinical trial outcome based on the hereditary predisposition of gynecologic cancer  ½Å¼ÒÁø(°è¸íÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:00~14:20 Clinical significance and reclassification of PV/LPV/VUS of BRCA 1/2  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:20~14:40 What should we know about real-world genetic counseling of hereditary gynecologic cancer?  Á¤°í¿î(±¹¸³¾Ï¼¾ÅÍ) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:40~14:50 Discussion  () 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 14:50~15:10 Genome & health record  È«°æ¿ø(Å׶óÁ¨ÀÌÅؽº) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:10~15:30 New treatment for hereditary gyencologic cancer  À¯¼±¿µ(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:30~15:50 Knowledge and anxiety in heritage ovarian cancer patients  ÀÌ»óÈñ(±¹¸³¾Ï¼¾ÅÍ) 
Åä·Ð 10¿ù 31ÀÏ ¿Â¶óÀÎ(°£È£ºÐ°ú Program) 15:50~16:00 Discussion  () 
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ÅëÇÕ Program) 16:40~16:50 Closing Remarks  () 
±âŸ 10¿ù 31ÀÏ ¿Â¶óÀÎ(ZOOM Meeting) 16:50~17:00 Á¤±âÃÑȸ (ZOOM Meeting)  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) Á¦26Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2020-10-31""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÀçÈ°ÀÇÇÐȸ 2020³â Ãß°èÇмú´ëȸ : 2020-10-31
´ÙÀ½±Û ´ëÇÑ°³¿øÀÇÇùÀÇȸ (¿Â¶óÀÎ) (Á÷¼±Á¦)´ëÇÑ»êºÎÀΰúÀÇ»çȸ 2020 Á¦5ȸ Àü±¹¼øȸ¼¼¹Ì³ª : 2020-10-31
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20620 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼­¿ï¾Æ»êº´¿ø ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-30 0 102 2024-04-30
20619 °æ³² »ï¼ºÃ¢¿øº´¿ø (¿Â¶óÀÎ)»ï¼ºÃ¢¿ø Ambulatory Pediatrics 2024 : 2024-06-29 0 81 2024-04-30
20618 °æºÏ Á¦8Â÷ ´ëÇѸðüžÆÀÇÇÐȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­ÁÂ(¿µ³²) : 2024-06-29 0 35 2024-04-30
20617 ¼­¿ï °Ç±¹´ëÇб³º´¿ø 2024 KUMC Precision Medicine Lung Cancer Conference : 2024-06-28 0 27 2024-04-30
20616 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ ÀûÇ÷±¸Áúȯ¿¬±¸ ½ÉÆ÷Áö¾ö : 2024-06-28 0 43 2024-04-30
20615 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚÇÑ µÎ°æºÎ¾Ï ȯÀÚÀÇ Ä¡·á ¹× °æ°ú : 2024-06-27 0 32 2024-04-30
20614 ¼­¿ï 2024³â ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 28 2024-04-30
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 64 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 46 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 51 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 45 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 35 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 43 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 46 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 30 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷